Androgen Deprivation Therapy News and Research

RSS
Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

Prostate cancer: Therapy depends on consulted specialty

Prostate cancer: Therapy depends on consulted specialty

RMEI and PIM sponsor education webcast on therapeutic considerations for CRPC

RMEI and PIM sponsor education webcast on therapeutic considerations for CRPC

Scientists identify new way to treat castrate resistant cells in prostate cancer patients

Scientists identify new way to treat castrate resistant cells in prostate cancer patients

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

ADT can worsen heart risk factors and may increase the risk of heart attack

ADT can worsen heart risk factors and may increase the risk of heart attack

Author evaluates potential benefits of IAD for treating prostate cancer

Author evaluates potential benefits of IAD for treating prostate cancer

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

New program to help maintain bone health in men with prostate cancer on ADT announced

New program to help maintain bone health in men with prostate cancer on ADT announced

GTx reports financial results for the third quarter of 2009

GTx reports financial results for the third quarter of 2009

FDA issues a Complete Response Letter for GTx' toremifene NDA

FDA issues a Complete Response Letter for GTx' toremifene NDA

Results of PCF funded study could impact the standard of care for prostate cancer patients

Results of PCF funded study could impact the standard of care for prostate cancer patients

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Gtx, Inc. reports Q2 2009 results

Gtx, Inc. reports Q2 2009 results

Study finds few patients die from prostate cancer within 15 years of radical prostatectomy

Study finds few patients die from prostate cancer within 15 years of radical prostatectomy

Prostate cancer therapy increases risk of fractures and cardiovascular-related death

Prostate cancer therapy increases risk of fractures and cardiovascular-related death

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Breast and prostate cancer treatment may result in bone loss

Breast and prostate cancer treatment may result in bone loss

Why hormone therapy for prostate cancer fails

Why hormone therapy for prostate cancer fails

Androgen deprivation therapy does not improve survival for elderly men with localized prostate cancer

Androgen deprivation therapy does not improve survival for elderly men with localized prostate cancer